Hosted on MSN

Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals

In the first nine months of 2025, Tempus AI Inc. TEM achieved several key regulatory milestones that strengthened its position in AI-driven diagnostics. In September 2025, the company received FDA 510 ...
Nasdaq

Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD

RNA sequencing provides a comprehensive view of biological information, offering deeper insights into disease mechanisms, including improved fusion detection. As a powerful tool in research and ...
Business Wire

Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) ...
Becker's Hospital Review

UC Davis to use precision medicine in pancreatic cancer care

Sacramento-based UC Davis Comprehensive Cancer Center will use next generation sequencing analysis on patients diagnosed with hematological malignancies and pancreatic cancer. The strategy will be ...
Becker's Hospital Review

Tempus, NYU Langone Health launch multiyear cancer research collaboration

Tempus and New York City-based NYU Langone Health have formed a multi-year strategic collaboration to advance cancer research through molecular profiling and data-driven insights. The partnership will ...